Cat. No.: HY-109566

AZD1390

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC₅₀ of 0.78 nM in cell.

For research use only. We do not sell to patients.

Purity: 99.22%
CAS No.: 2089288-03-7
Formula: C₂₇H₃₂FN₅O₂
Molecular Weight:477.57

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

AZD1390 Chemical Structure

CAS No.: 2089288-03-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC₅₀ of 0.78 nM in cell^[1].

IC₅₀ & Target^[1]

ATM

All ATM/ATR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
A549	IC₅₀	43 μM Compound: AZD1390	Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
COLO 205	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HCT-116	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
HCT-116	IC₅₀	10.5 μM Compound: AZD1390	Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HCT-116 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 36462444]
HT-29	IC₅₀	>10 μM Compound: AZD1390	Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ATM proficient human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35183872]
HT-29	IC₅₀	>10 μM Compound: AZD1390	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CCK-8 assay	[PMID: 37130473]
HT-29	IC₅₀	>30 μM Compound: AZD1390	Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay Antiproliferative activity against ATM-proficient human HT-29 cells assessed as reduction in cell proliferation incubated for 3 days by MTT assay	[PMID: 36462444]
K562	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
LoVo	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
NCI-H358	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
RKO	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW13	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW480	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]
SW-620	IC₅₀	>20 μM Compound: AZD1390	Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38634707]

In Vivo

Median survival of mice treated with AZD1390 and radiation are significantly longer than untreated control mice (p=0.001). No overt signs of treatment toxicity are observed with small animal radiation research platform (SARRP) contrary to wholehead irradiated mice that seem to develop mucositis and difficulties drinking and eating at doses >10 Gy in combination with AZD1390^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2089288-03-7
Appearance Solid
Molecular Weight 477.57
Formula C₂₇H₃₂FN₅O₂
Color White to off-white
SMILES

O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (10)

All WBIPCell Imaging/StainingOthersIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer. [Abstract]

2025 Jun 13;10(1):185. PMID: 40506449

AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]

Immunoblot analysis was performed on cell lysates extracted from ANV5-OE cells at different time points after treatment with IR (2 Gy), IR/ENPP1i (5 µM), IR/ATMi (AZD1390: 5 µM), or triple therapy to detect the protein expression levels of γHA2X, PARP1, cleaved PARP1 (c-PARP), ENPP1, RAD51, GAPDH, and Tubulin.

AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]

The number of positive cells labeled with anti-γH2AX antibody was quantitatively assessed. Cells were incubated with ENPP1i (5 µM) and ATMi (AZD1390: 5 µM) for 24 h.

AZD1390 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]

After orthotopic transplantation of OE-ANV5 cells, mice were treated with FD (6.2 Gy × 4) alone, or in combination with ENPP1i (6 mg/kg, twice daily), ATMi (AZD1390: 5 mg/kg, once daily), or triple therapy (n = 8 mice per group), and changes in tumor volume were observed.
Nat Nanotechnol

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. [Abstract]

2021 Jul;16(7):830-839. PMID: 33958764
EMBO J

DNA-PKcs and ATM modulate mitochondrial ADP-ATP exchange as an oxidative stress checkpoint mechanism. [Abstract]

2023 Mar 15;42(6):e112094. PMID: 36727301

AZD1390 purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]

HeLa cells expressing Flag‐tagged VDAC2 and V5‐tagged ANT2 were subjected to Co‐IP using anti‐Flag antibody and analyzed by western blot as indicated. ANT2, but not VDAC2, temporarily dissociated from DNA‐PKcs after treatment of 10 Gy IR. ATM knockdown and inhibition (AZD1390, 10 nM) disrupted the dissociation.

AZD1390 purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]

Primary mouse embryonic fibroblasts (MEF) RPE-1 were analyzed for ADP-ATP exchange activity at different time points (up to 16 hours) in response to 100 μM H₂O₂. The ATM inhibitor (AZD1390, 10 nM) was also included in the parallel analysis.
J Med Chem

Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors. [Abstract]

2024 May 9;67(9):7620-7634. PMID: 38634707
Int J Radiat Oncol Biol Phys

Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma. [Abstract]

2023 Mar 15;115(4):957-971. PMID: 36368436
CNS Neurosci Ther

AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia-mediated neuroinflammation and ischemic brain injury. [Abstract]

2024 Apr;30(4):e14696. PMID: 38668740
Shock

ATAXIA TELANGIECTASIA MUTATED PROTECTS AGAINST LIPOPOLYSACCARIDE-INDUCED BLOOD-BRAIN BARRIER DISRUPTION BY REGULATING ATK/DRP1-MEDIATED MITOCHONDRIAL HOMEOSTASIS. [Abstract]

2023 Jul 1;60(1):100-109. PMID: 37141173
EANM Innovation

2026 May 19;3:100274.
University of Califomia San Francisco

2026.
bioRxiv

2025 Jul 31.

Solvent & Solubility

In Vitro:

DMSO : 5 mg/mL (10.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0939 mL

10.4697 mL

20.9393 mL

5 mM

0.4188 mL

2.0939 mL

4.1879 mL

10 mM

0.2094 mL

1.0470 mL

2.0939 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 5 mg/mL (10.47 mM); Suspended solution; Need ultrasonic

Protocol

Animal Administration^[2]

Mouse GL261 glioma (p53 mutant) cells are implanted intra-cranially into immunocompetent, syngeneic C57/bl6 mice followed by bioluminescent imaging (BLI) prior to randomization. AZD1390 is administered by oral gavage prior to deliver multiple fractions of 2-3 Gy of radiation on 2 to 4 consecutive days. Radiation is administered via small animal radiation research platform (SARRP) irradiation to the site of the tumor with a 5×5 mm lateral ﬁeld^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Durant ST, et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv. 2018 Jun 20;4(6):eaat1719. [Content Brief]

[2]. J. Kahn, et al. Next-Generation ATM Kinase Inhibitors Under Development Radiosensitize Glioblastoma With Conformal Radiation in a Mouse Orthotopic Model. IJROBP. 2017. 99, 600-601.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0939 mL	10.4697 mL	20.9393 mL	52.3483 mL
	5 mM	0.4188 mL	2.0939 mL	4.1879 mL	10.4697 mL
	10 mM	0.2094 mL	1.0470 mL	2.0939 mL	5.2348 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

AZD1390

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) AZD1390

All ATM/ATR Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

AZD1390 Related Classifications

Cat. No.: HY-109566